Thiazolidinedione Use in Individuals With Type 2 Diabetes and Chronic Obstructive Pulmonary Disease

doi:10.3389/fmed.2021.729518

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24095

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24095

Title:	Thiazolidinedione Use in Individuals With Type 2 Diabetes and Chronic Obstructive Pulmonary Disease
Authors:	Yen, FS;Wei, JCC;Yang, YC;Hsu, CC;Hwu, CM
Keywords:	mortality;stroke;coronary artery disease;heart failure;non-invasive positive pressure ventilation;invasive mechanical ventilation;bacterial pneumonia;lung cancer
Date:	2021
Issue Date:	2022-08-05T09:47:45Z (UTC)
Publisher:	FRONTIERS MEDIA SA
Abstract:	Few studies have investigated the effects of various antidiabetic agents on individuals with both type 2 diabetes mellitus (T2DM) and Chronic obstructive pulmonary disease (COPD). This study compared mortality, cardiovascular events and respiratory outcomes in individuals with both T2DM and COPD taking TZD vs. those not taking TZD. From Taiwan's National Health Insurance Research Database, 12 856 propensity-score-matched TZD users and non-users were selected between January 1, 2000, and December 31, 2012. Cox proportional hazards models were used to calculate the risks of investigated outcomes. Compared with non-use of TZD, the adjusted hazard ratios (95% CI) of TZD use were stroke 1.63 (1.21-2.18), coronary artery disease 1.55 (1.15-2.10), heart failure 1.61 (1.06-2.46), non-invasive positive pressure ventilation 1.82 (1.46-2.27), invasive mechanical ventilation 1.23 (1.09-1.37), bacterial pneumonia 1.55 (1.42-1.70), and lung cancer 1.71 (1.32-2.22), respectively. The stratified analysis disclosed that rosiglitazone, not pioglitazone, was associated with significantly higher risk of major cardiovascular events than TZD non-users. In patients with concomitant T2DM and COPD, TZD use was associated with higher risks of cardiovascular events, ventilation use, pneumonia, and lung cancer. Use of TZD in these patients should be supported by monitoring for cardiovascular and respiratory complications.
URI:	http://dx.doi.org/10.3389/fmed.2021.729518 https://www.webofscience.com/wos/woscc/full-record/WOS:000738166200001 https://ir.csmu.edu.tw:8080/handle/310902500/24095
Relation:	FRONTIERS IN MEDICINE ,2021,v8
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	195	View/Open

Loading...